Inhaled medication and inhalation devices for lung disease in patients with cystic fibrosis: A European consensus

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Inhaled medication and inhalation devices for lung disease in patients with cystic fibrosis: A European consensus. / Heijerman, Harry; Westerman, Elsbeth; Conway, Steven; Touw, Daan; Döring, Gerd; Høiby, Niels; consensus working group.

In: Journal of Cystic Fibrosis, Vol. 8, No. 5, 2009, p. 295-315.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Heijerman, H, Westerman, E, Conway, S, Touw, D, Döring, G, Høiby, N & consensus working group 2009, 'Inhaled medication and inhalation devices for lung disease in patients with cystic fibrosis: A European consensus', Journal of Cystic Fibrosis, vol. 8, no. 5, pp. 295-315. https://doi.org/10.1016/j.jcf.2009.04.005

APA

Heijerman, H., Westerman, E., Conway, S., Touw, D., Döring, G., Høiby, N., & consensus working group (2009). Inhaled medication and inhalation devices for lung disease in patients with cystic fibrosis: A European consensus. Journal of Cystic Fibrosis, 8(5), 295-315. https://doi.org/10.1016/j.jcf.2009.04.005

Vancouver

Heijerman H, Westerman E, Conway S, Touw D, Döring G, Høiby N et al. Inhaled medication and inhalation devices for lung disease in patients with cystic fibrosis: A European consensus. Journal of Cystic Fibrosis. 2009;8(5):295-315. https://doi.org/10.1016/j.jcf.2009.04.005

Author

Heijerman, Harry ; Westerman, Elsbeth ; Conway, Steven ; Touw, Daan ; Döring, Gerd ; Høiby, Niels ; consensus working group. / Inhaled medication and inhalation devices for lung disease in patients with cystic fibrosis: A European consensus. In: Journal of Cystic Fibrosis. 2009 ; Vol. 8, No. 5. pp. 295-315.

Bibtex

@article{e5536ed0aabf11df928f000ea68e967b,
title = "Inhaled medication and inhalation devices for lung disease in patients with cystic fibrosis: A European consensus",
abstract = "In cystic fibrosis inhalation of drugs for the treatment of CF related lung disease has been proven to be highly effective. Consequently, an increasing number of drugs and devices have been developed for CF lung disease or are currently under development. In this European consensus document we review the current status of inhaled medication in CF, including the mechanisms of action of the various drugs, their modes of administration and indications, their effects on lung function, exacerbation rates, survival and quality of life, as well as side effects. Specifically we address antibiotics, mucolytics/mucous mobilizers, anti-inflammatory drugs, bronchodilators and combinations of solutions. Additionally, we review the current knowledge on devices for inhalation therapy with regard to optimal particle sizes and characteristics of wet nebulisers, dry powder and metered dose inhalers. Finally, we address the subject of testing new devices before market introduction.",
author = "Harry Heijerman and Elsbeth Westerman and Steven Conway and Daan Touw and Gerd D{\"o}ring and Niels H{\o}iby and {consensus working group}",
note = "Keywords: Administration, Inhalation; Anti-Bacterial Agents; Anti-Inflammatory Agents; Bronchodilator Agents; Cystic Fibrosis; Drug Combinations; Expectorants; Humans; Lung Diseases; Nebulizers and Vaporizers; Respiratory System Agents",
year = "2009",
doi = "10.1016/j.jcf.2009.04.005",
language = "English",
volume = "8",
pages = "295--315",
journal = "Journal of Cystic Fibrosis",
issn = "1569-1993",
publisher = "Elsevier",
number = "5",

}

RIS

TY - JOUR

T1 - Inhaled medication and inhalation devices for lung disease in patients with cystic fibrosis: A European consensus

AU - Heijerman, Harry

AU - Westerman, Elsbeth

AU - Conway, Steven

AU - Touw, Daan

AU - Döring, Gerd

AU - Høiby, Niels

AU - consensus working group

N1 - Keywords: Administration, Inhalation; Anti-Bacterial Agents; Anti-Inflammatory Agents; Bronchodilator Agents; Cystic Fibrosis; Drug Combinations; Expectorants; Humans; Lung Diseases; Nebulizers and Vaporizers; Respiratory System Agents

PY - 2009

Y1 - 2009

N2 - In cystic fibrosis inhalation of drugs for the treatment of CF related lung disease has been proven to be highly effective. Consequently, an increasing number of drugs and devices have been developed for CF lung disease or are currently under development. In this European consensus document we review the current status of inhaled medication in CF, including the mechanisms of action of the various drugs, their modes of administration and indications, their effects on lung function, exacerbation rates, survival and quality of life, as well as side effects. Specifically we address antibiotics, mucolytics/mucous mobilizers, anti-inflammatory drugs, bronchodilators and combinations of solutions. Additionally, we review the current knowledge on devices for inhalation therapy with regard to optimal particle sizes and characteristics of wet nebulisers, dry powder and metered dose inhalers. Finally, we address the subject of testing new devices before market introduction.

AB - In cystic fibrosis inhalation of drugs for the treatment of CF related lung disease has been proven to be highly effective. Consequently, an increasing number of drugs and devices have been developed for CF lung disease or are currently under development. In this European consensus document we review the current status of inhaled medication in CF, including the mechanisms of action of the various drugs, their modes of administration and indications, their effects on lung function, exacerbation rates, survival and quality of life, as well as side effects. Specifically we address antibiotics, mucolytics/mucous mobilizers, anti-inflammatory drugs, bronchodilators and combinations of solutions. Additionally, we review the current knowledge on devices for inhalation therapy with regard to optimal particle sizes and characteristics of wet nebulisers, dry powder and metered dose inhalers. Finally, we address the subject of testing new devices before market introduction.

U2 - 10.1016/j.jcf.2009.04.005

DO - 10.1016/j.jcf.2009.04.005

M3 - Journal article

C2 - 19559658

VL - 8

SP - 295

EP - 315

JO - Journal of Cystic Fibrosis

JF - Journal of Cystic Fibrosis

SN - 1569-1993

IS - 5

ER -

ID: 21456434